TY - JOUR
T1 - Defining Benchmarks in Liver Transplantation
T2 - A Multicenter Outcome Analysis Determining Best Achievable Results
AU - Muller, Xavier
AU - Marcon, Francesca
AU - Sapisochin, Gonzalo
AU - Marquez, Max
AU - Dondero, Federica
AU - Rayar, Michel
AU - Doyle, Majella M.B.
AU - Callans, Lauren
AU - Li, Jun
AU - Nowak, Greg
AU - Allard, Marc Antoine
AU - Jochmans, Ina
AU - Jacskon, Kyle
AU - Beltrame, Magali Chahdi
AU - Van Reeven, Marjolein
AU - Iesari, Samuele
AU - Cucchetti, Alessandro
AU - Sharma, Hemant
AU - Staiger, Roxane D.
AU - Raptis, Dimitri A.
AU - Petrowsky, Henrik
AU - De Oliveira, Michelle
AU - Hernandez-Alejandro, Roberto
AU - Pinna, Antonio D.
AU - Lerut, Jan
AU - Polak, Wojciech G.
AU - De Santibañes, Eduardo
AU - De Santibañes, Martín
AU - Cameron, Andrew M.
AU - Pirenne, Jacques
AU - Cherqui, Daniel
AU - Adam, René A.
AU - Ericzon, Bö Göran
AU - Nashan, Bjoern
AU - Olthoff, Kim
AU - Shaked, Avi
AU - Chapman, William C.
AU - Boudjema, Karim
AU - Soubrane, Olivier
AU - Paugam-Burtz, Catherine
AU - Greig, Paul D.
AU - Grant, David R.
AU - Carvalheiro, Amanda
AU - Muiesan, Paolo
AU - Dutkowski, Philipp
AU - Puhan, Milo
AU - Clavien, Pierre Alain
N1 - Publisher Copyright:
© 2017 Wolters Kluwer Health, Inc. All rights reserved.
PY - 2018/3/1
Y1 - 2018/3/1
N2 - Objective: To propose benchmark outcome values in liver transplantation, serving as reference for assessing individual patients or any other patient groups. Background: Best achievable results in liver transplantation, that is, benchmarks, are unknown. Consequently, outcome comparisons within or across centers over time remain speculative. Methods: Out of 7492 liver transplantation performed in 17 international centers from 3 continents, we identified 2024 low risk adult cases with a laboratory model for end-stage liver disease score ≤20 points, a balance of risk score ≤9, and receiving a primary graft by donation after brain death. We chose clinically relevant endpoints covering intra- and postoperative course, with a focus on complications graded by severity including the complication comprehensive index (CCI ®). Respective benchmarks were derived from the median value in each center, and the 75 percentile was considered the benchmark cutoff. Results: Benchmark cases represented 8% to 49% of cases per center. One-year patient-survival was 91.6% with 3.5% retransplantations. Eighty-two percent of patients developed at least 1 complication during 1-year follow-up. Biliary complications occurred in one-fifth of the patients up to 6 months after surgery. Benchmark cutoffs were ≤4 days for ICU stay, ≤18 days for hospital stay, ≤59% for patients with severe complications (≥ Grade III) and ≤42.1 for 1-year CCI ®. Comparisons with the next higher risk group (model for end stage liver disease 21-30) disclosed an increase in morbidity but within benchmark cutoffs for most, but not all indicators, while in patients receiving a second graft from 1 center (n = 50) outcome values were all outside of benchmark values. Conclusions: Despite excellent 1-year survival, morbidity in benchmark cases remains high with half of patients developing severe complications during 1-year follow-up. Benchmark cutoffs targeting morbidity parameters offer a valid tool to assess higher risk groups.
AB - Objective: To propose benchmark outcome values in liver transplantation, serving as reference for assessing individual patients or any other patient groups. Background: Best achievable results in liver transplantation, that is, benchmarks, are unknown. Consequently, outcome comparisons within or across centers over time remain speculative. Methods: Out of 7492 liver transplantation performed in 17 international centers from 3 continents, we identified 2024 low risk adult cases with a laboratory model for end-stage liver disease score ≤20 points, a balance of risk score ≤9, and receiving a primary graft by donation after brain death. We chose clinically relevant endpoints covering intra- and postoperative course, with a focus on complications graded by severity including the complication comprehensive index (CCI ®). Respective benchmarks were derived from the median value in each center, and the 75 percentile was considered the benchmark cutoff. Results: Benchmark cases represented 8% to 49% of cases per center. One-year patient-survival was 91.6% with 3.5% retransplantations. Eighty-two percent of patients developed at least 1 complication during 1-year follow-up. Biliary complications occurred in one-fifth of the patients up to 6 months after surgery. Benchmark cutoffs were ≤4 days for ICU stay, ≤18 days for hospital stay, ≤59% for patients with severe complications (≥ Grade III) and ≤42.1 for 1-year CCI ®. Comparisons with the next higher risk group (model for end stage liver disease 21-30) disclosed an increase in morbidity but within benchmark cutoffs for most, but not all indicators, while in patients receiving a second graft from 1 center (n = 50) outcome values were all outside of benchmark values. Conclusions: Despite excellent 1-year survival, morbidity in benchmark cases remains high with half of patients developing severe complications during 1-year follow-up. Benchmark cutoffs targeting morbidity parameters offer a valid tool to assess higher risk groups.
KW - benchmark
KW - complication
KW - liver transplantation
KW - morbidity
KW - outcome
UR - http://www.scopus.com/inward/record.url?scp=85042412332&partnerID=8YFLogxK
U2 - 10.1097/SLA.0000000000002477
DO - 10.1097/SLA.0000000000002477
M3 - Article
C2 - 28885508
AN - SCOPUS:85042412332
SN - 0003-4932
VL - 267
SP - 419
EP - 425
JO - Annals of surgery
JF - Annals of surgery
IS - 3
ER -